British Columbia

British Columbia (BC) has emerged as a global life sciences hub, distinguished by its rapid growth and world-leading innovations in biotechnology and pharmaceutical development.

As a pioneer in genomics and precision medicine, the province is internationally recognized for its breakthrough work in lipid nanoparticle (LNP) technology and mRNA vaccine delivery systems, which were instrumental in the global response to COVID-19.

The ecosystem is anchored by the University of British Columbia (UBC), a top-ranked academic institution that fuels a steady pipeline of specialized talent and high-impact health research.

Vancouver’s thriving biopharmaceutical sector is complemented by a robust medical device industry, where companies excel in developing advanced diagnostics, digital health solutions and AI-driven healthcare innovation.

The province's Life Sciences and Biomanufacturing Strategy has significantly expanded domestic biomanufacturing capacity, facilitating a seamless transition of therapies from "bench to bedside."

Investors and partners benefit from a highly collaborative network of over 50 research centers of excellence and world-class clinical trial infrastructure.

With its strategic Pacific Gateway location and competitive tax credits for R&D, British Columbia offers a dynamic environment for life sciences startups and established global anchor companies alike.

The sector continues to set benchmarks in immuno-oncology, antibody discovery and regenerative medicine, making it a vital destination for international life sciences investment.